Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CODX OTCMKTS:ESMC NASDAQ:LUCY NASDAQ:LYRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCODXCo-Diagnostics$0.25-1.9%$0.27$0.23▼$2.23$8.44M0.511.44 million shs245,801 shsESMCEscalon Medical$0.27$0.33$0.11▼$0.46$2M0.439,529 shsN/ALUCYInnovative Eyewear$1.97+0.5%$2.33$1.57▼$11.16$8.97M3.21147,395 shs86,474 shsLYRALyra Therapeutics$6.89+1.6%$10.88$3.81▼$37.50$10.84M0.1633,292 shs26,767 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCODXCo-Diagnostics-1.91%-4.60%-11.96%-27.42%-76.94%ESMCEscalon Medical0.00%-15.94%-22.86%+45.95%+62.65%LUCYInnovative Eyewear+0.51%-3.90%-9.22%+7.65%-50.63%LYRALyra Therapeutics+1.62%+2.84%-25.51%+40.33%-55.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCODXCo-Diagnostics3.963 of 5 stars3.53.00.04.41.50.01.3ESMCEscalon MedicalN/AN/AN/AN/AN/AN/AN/AN/ALUCYInnovative Eyewear0.076 of 5 stars0.02.00.00.00.00.00.6LYRALyra Therapeutics3.3422 of 5 stars3.25.00.00.01.82.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCODXCo-Diagnostics 3.00Buy$5.502,129.43% UpsideESMCEscalon Medical 0.00N/AN/AN/ALUCYInnovative Eyewear 0.00N/AN/AN/ALYRALyra Therapeutics 2.33Hold$100.001,351.38% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCODXCo-Diagnostics$3.91M2.12N/AN/A$1.70 per share0.15ESMCEscalon Medical$11.98M0.17$0.04 per share7.49N/A∞LUCYInnovative Eyewear$1.64M5.49N/AN/A$3.72 per share0.53LYRALyra Therapeutics$1.53M7.21N/AN/A$8.86 per share0.78Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCODXCo-Diagnostics-$37.64M-$1.17N/AN/AN/A-1,025.45%-60.16%-52.69%8/14/2025 (Estimated)ESMCEscalon Medical-$130K$0.055.40∞N/A4.70%45.60%12.66%N/ALUCYInnovative Eyewear-$7.77M-$3.99N/A∞N/A-443.18%-86.90%-81.36%8/11/2025 (Estimated)LYRALyra Therapeutics-$93.43M-$60.50N/AN/AN/A-6,711.39%-295.52%-66.95%8/13/2025 (Estimated)Latest ESMC, LUCY, LYRA, and CODX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025CODXCo-Diagnostics-$0.25N/AN/AN/A$0.30 millionN/A8/13/2025Q2 2025LYRALyra Therapeutics-$5.79N/AN/AN/A$0.18 millionN/A5/14/2025Q3 2025ESMCEscalon MedicalN/A$0.02N/A$0.02N/A$3.47 million5/13/2025Q1 2025LUCYInnovative Eyewear-$0.73-$0.72+$0.01-$0.72$1.00 million$0.46 million5/8/2025Q1 2025CODXCo-Diagnostics-$0.33-$0.24+$0.09-$0.24$0.38 million$0.05 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCODXCo-DiagnosticsN/AN/AN/AN/AN/AESMCEscalon MedicalN/AN/AN/AN/AN/ALUCYInnovative EyewearN/AN/AN/AN/AN/ALYRALyra TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCODXCo-DiagnosticsN/A4.434.23ESMCEscalon Medical0.141.921.23LUCYInnovative EyewearN/A16.4013.02LYRALyra TherapeuticsN/A2.962.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCODXCo-Diagnostics14.99%ESMCEscalon MedicalN/ALUCYInnovative Eyewear0.96%LYRALyra Therapeutics95.62%Insider OwnershipCompanyInsider OwnershipCODXCo-Diagnostics8.40%ESMCEscalon Medical1.90%LUCYInnovative Eyewear1.66%LYRALyra Therapeutics3.25%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCODXCo-Diagnostics10033.57 million30.75 millionOptionableESMCEscalon Medical407.42 million7.27 millionNot OptionableLUCYInnovative Eyewear94.57 million4.50 millionNot OptionableLYRALyra Therapeutics501.60 million1.55 millionOptionableESMC, LUCY, LYRA, and CODX HeadlinesRecent News About These CompaniesLyra Therapeutics (NASDAQ:LYRA) Shares Up 3.8% - What's Next?August 5 at 3:47 AM | americanbankingnews.comLyra Therapeutics Board Chair Waksal Steps DownAugust 2, 2025 | marketwatch.comLyra Therapeutics Announces Leadership Changes in August 2025August 2, 2025 | msn.comLyra Therapeutics, Inc. (NASDAQ:LYRA) CEO Sells $13,944.15 in StockJuly 15, 2025 | insidertrades.comLyra Therapeutics, Inc. Announces Definitive Agreement for Registered Direct Offering and Private Placement of Common Stock and Warrants - NasdaqJune 29, 2025 | nasdaq.comLyra Therapeutics to raise up to $15M via registered direct offering and concurrent private placement, stock falls 22%June 27, 2025 | msn.comLyra Therapeutics, Inc. Announces Definitive Agreement for Registered Direct Offering and Private Placement of Common Stock and WarrantsJune 27, 2025 | quiverquant.comQLyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq RulesJune 27, 2025 | globenewswire.comLyra Therapeutics Regains Nasdaq Compliance in June 2025June 23, 2025 | tipranks.comLyra Therapeutics: Regulatory Pathway For Non-Polyp Patients, An Underappreciated CatalystJune 16, 2025 | seekingalpha.comLyra Therapeutics (LYRA) Upgraded to Buy: Here's WhyJune 12, 2025 | zacks.comH.C. Wainwright lifts Lyra Therapeutics stock target to $16June 11, 2025 | investing.comLyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study SuccessJune 5, 2025 | zacks.comLyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in ...June 4, 2025 | seekingalpha.comLyra Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:LYRA | BenzingaJune 3, 2025 | benzinga.comLyra Therapeutics (NASDAQ:LYRA) Stock, Insider Trading ActivityJune 3, 2025 | benzinga.comAsian markets rise as US stocks near records on easing trade tensionsJune 2, 2025 | business-standard.comBLyra Therapeutics Stock Skyrockets On Positive Trial Data For Its Nasal Implant: Retail’s ThrilledJune 2, 2025 | msn.comWall Street drifts higher as oil prices jump and US manufacturing slumpsJune 2, 2025 | msn.comWhy Did Lyra Therapeutics’ Stock Rocket Past 440% in Premarket TodayJune 2, 2025 | tokenist.comTNew MarketBeat Followers Over TimeMedia Sentiment Over TimeESMC, LUCY, LYRA, and CODX Company DescriptionsCo-Diagnostics NASDAQ:CODX$0.25 0.00 (-1.91%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$0.26 +0.01 (+4.18%) As of 08/7/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.Escalon Medical OTCMKTS:ESMC$0.27 0.00 (0.00%) As of 08/5/2025Escalon Medical Corp. engages in the development, manufacturing, marketing, and distribution of medical devices and pharmaceuticals in the area of ophthalmology in the United States and internationally. It offers A-Scan, which provides information about the internal structure of the eye; B-Scan, a diagnostic tool that supplies information to physicians where the media within the eye are cloudy or opaque; UBM, a high frequency/high resolution ultrasound device, which provides detailed information about the anterior segment of the eye; and Pachymeter that measures the thickness of cornea. The company also provides Ispan Intraocular Gases, such as C3F8 and SF6 that are used by vitreoretinal surgeons as a temporary tamponade in detached retina surgery; and AXIS Image management system for managing ophthalmic diagnostic images through the web browser from various devices. In addition, it markets disposable surgical packs used in vitreoretinal surgery, including packs that aid surgeons in the process of injecting and extracting silicone oil. Further, the company engages in the manufacturing and distribution of patented disposable universal gas kit, which delivers the gas from the canister to the patient. It sells its products to medical institutions through independent sales representatives, network of distributors, and internal sales employees. Escalon Medical Corp. was incorporated in 1987 and is headquartered in Wayne, Pennsylvania.Innovative Eyewear NASDAQ:LUCY$1.97 +0.01 (+0.51%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$1.97 0.00 (0.00%) As of 08/7/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Innovative Eyewear, Inc. develops and sells smart eyeglasses and sunglasses. The company's flagship product is Lucyd Lyte glasses that enable the wearer to listen to music, take and make calls, and use voice assistants to perform various smartphone tasks hands-free. It also offers Vyrb, a social media application that enables the user to receive and send posts through Lucyd Lyte smart glasses with voice. In addition, the company launches an application, Lucyd app for iOS/Android users. It sells its products through various e-commerce, and retail store and distribution channels. Innovative Eyewear, Inc. has a license agreement with Lucyd Ltd. The company was incorporated in 2019 and is headquartered in North Miami, Florida. Innovative Eyewear, Inc. is a subsidiary of Lucyd Ltd.Lyra Therapeutics NASDAQ:LYRA$6.89 +0.11 (+1.62%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$6.89 0.00 (-0.01%) As of 08/7/2025 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Constellation Energy’s Earnings Beat Signals a New Era AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down Realty Income Rallies Post-Earnings Miss—Here’s What Drove It Don't Mix the Signal for Noise in Super Micro Computer's Earnings Microsoft Stock Gains as Analysts Boost Price Targets Joby Deal Gives Blade New Direction, But Stock Lacks Lift Uber Technologies Is Driving Cash Flow: Ride It Higher for Life How DigitalOcean's Focus Is Fueling Explosive Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
